RxDoctor Payments Data

David Echeverri, MD

Family Medicine · Charlotte, NCNPI 1538665203

Payments from drug & device makers

$3,415in general payments, 2019–2025

Across 205 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$937
  • Novo Nordisk$489
  • Pfizer$422
  • GSK$282
  • Lilly USA, LLC$224
  • Theratechnologies Inc.$139
  • plus $921 from 26 others

What the payments were for

  • Food & beverage$3,415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,415 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$94,481
Medicare patients
306
Services billed
1,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5035$412,865
MounjaroTirzepatide78$93,700
Egrifta SvTesamorelin Acetate12$87,951
JardianceEmpagliflozin84$81,693
OzempicSemaglutide46$70,139
TrulicityDulaglutide50$50,350
EliquisApixaban59$37,856
FarxigaDapagliflozin Propanediol47$35,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$23,495
JanuviaSitagliptin Phosphate15$18,511
Repatha SureclickEvolocumab11$6,628
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,994
Atorvastatin Calcium364$4,180
Tresiba Flextouch U-100Insulin Degludec12$4,136
Breo ElliptaFluticasone/Vilanterol11$3,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$224$144,050128 claims
Theratechnologies Inc.Egrifta Sv$139$87,95112 claims
Boehringer IngelheimJardiance$71$81,69384 claims
Novo NordiskOzempic$489$70,13946 claims
PfizerEliquis$422$37,85659 claims
AstraZenecaFarxiga$14$35,25247 claims
GSKTrelegy Ellipta, Breo Ellipta$282$27,10737 claims
AbbVieSynthroid$937$2,84427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →